U.S. Neuroendoscopy Devices Market (2026 - 2033)

U.S. Neuroendoscopy Devices Market Size & Trends

The U.S. neuroendoscopy devices market size was valued at USD 27.0 million in 2025 and is projected to grow from USD 28.6 million in 2026 to USD 43.3 million by 2033, at a CAGR of 6.1% from 2026 to 2033. The market growth is driven by the adoption of endoscopic visualization in intraventricular procedures, transnasal surgery, skull-base interventions, and selected intracranial applications. Advances in endoscopic imaging and the development of procedure-specific rigid and flexible neuroendoscopes support demand for improved visualization in minimally invasive neurosurgery. Demand for reusable instruments is also supported by equipment replacement and upgrades, while single-use devices may provide an additional growth avenue as their adoption expands.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

The U.S. neuroendoscopy devices market is driven by the growing adoption of minimally invasive neurosurgical procedures, including ventricular endoscopy, transsphenoidal surgery, and endonasal skull-base interventions. Advances in high-definition imaging, compact endoscopes, and procedure-specific instruments are supporting improved visualization and surgical precision. However, high equipment costs, the need for specialized surgical training, and technical limitations in complex procedures may restrain market growth. Opportunities are emerging through continued product innovation, equipment upgrades, and the development of single-use neuroendoscopic devices.

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion.

The U.S. neuro endoscopy devices market is characterized by a high degree of innovation, supported by the development of three-dimensional imaging and advanced digital visualization systems. For instance, in May 2025, the FDA granted 510(k) clearance to HJY Smart Medical Device Co., Ltd.'s VisualNext 3D Endoscopic Vision System, which is classified as a Class II neurological endoscope and supports 2D and 3D visualization during neurological and spinal procedures.

To learn more about this report, Download Free Sample Report

The market is characterized by moderate merger and acquisition activity, as established medical technology companies pursue complementary surgical technologies and digital visualization capabilities to expand their portfolios. For instance, in August 2024, KARL STORZ completed its acquisition of Asensus Surgical, strengthening its capabilities in robotic-assisted surgery and digital surgical technologies.

"We are thrilled to complete this merger with KARL STORZ, which marks an exciting new chapter for Asensus, By joining forces with a leading company in endoscopy that became a system provider for integrated MedTech, we are well-positioned to accelerate the development and delivery of our innovative robotic and digital surgical solutions. This union will benefit patients and surgeons worldwide by advancing precise, safer, and more predictable surgical outcomes."

-Anthony Fernando, Asensus Surgical President and CEO.

The U.S. neuroendoscopy devices market is subject to significant regulatory oversight, as medical devices must meet applicable FDA requirements before commercial distribution. For instance, in April 2025, the FDA granted 510(k) clearance to Integra LifeSciences' AURORA Surgiscope System (ASX15/60 and ASX15/80), classified as a Class II neurological endoscope for neurosurgical and neuroendoscopic applications. These regulatory requirements influence product development, market entry timelines, and manufacturers' compliance costs.

The U.S. market is characterized by moderate substitution pressure, owing to the availability of exoscopic visualization systems for selected neurosurgical procedures. For instance, in December 2024, KARL STORZ received Vizient’s Innovative Technology Designation for the VITOM eagle exoscope with ARTip CRUISE, a 4K/3D/ICG visualization system designed to support exoscopic and endoscopic visualization through the IMAGE1 S platform.

Analyst Perspective

The U.S. neuroendoscopy devices market is driven by the growing use of endoscopic techniques across ventricular, intracranial, and skull-base procedures, with hospitals serving as the primary demand center due to their neurosurgical infrastructure and multidisciplinary care capabilities. Demand is rising for applications such as endoscopic third ventriculostomy, ventricular interventions, tumor procedures, hemorrhage evacuation, and endoscopic skull-base surgery. The existing installed base of reusable rigid and flexible neuro endoscopes generates recurring demand through replacement, repair, and system expansion, while disposable platforms introduce a procedure-based purchasing model supported by reduced reprocessing requirements and immediate availability. Product selection is increasingly influenced by clinical application, maneuverability, visualization quality, working-channel functionality, compatibility with existing equipment, and procedure economics.

Product Type Insights

The rigid neuroendoscopes segment accounted for the largest share of around 71.3% in 2025, driven by their established use in ventricular, cranial, and skull-base procedures. Rigid systems provide stable visualization and precise access through surgical corridors, supporting their continued use across neurosurgical procedures. For instance, in June 2026, Stryker received U.S. FDA clearance for its Precision S 4K Sinuscope under the neurological endoscope classification, reflecting continued development of high-resolution rigid endoscopic visualization for neurosurgical applications.

The flexible neuro endoscopes segment is expected to grow at fastest CAGR over the forecast period from 2026 to 2033. This growth is driven by the maneuverability of flexible and steerable systems in procedures involving complex intracranial anatomy. Flexible neuro endoscopes support ventricular and selected non-ventricular cerebral procedures requiring access to anatomically difficult areas. For instance, in August 2024, researchers from the University of Wisconsin-Madison reported a mother-daughter ventricular endoscopy technique in Operative Neurosurgery. The technique uses a smaller endoscope through a larger endoscope to improve visualization and access within the ventricular system, addressing anatomical constraints encountered during conventional rigid endoscopy.

Setting Insights

The hospital segment accounted for the largest revenue share of 98.1% in 2025, due to the concentration of complex neurosurgical procedures and the availability of specialized operating rooms, neurosurgical teams, and perioperative support. Neuro endoscopic procedures, including endoscopic endonasal skull base surgery, generally require hospital-based infrastructure for surgical intervention and postoperative management. For instance, in May 2025, UPMC’s Center for Cranial Base Surgery performed its 5,000th endoscopic endonasal approach (EEA) skull base surgery at UPMC Presbyterian Hospital, reflecting the established use of hospital settings for endoscopic neurosurgical procedures.

The neurosurgical centers / specialty centers segment is expected to grow at fastest in CAGR over the forecast period from 2026 to 2033, owing to the expansion of specialized neurosurgical services and dedicated treatment facilities. The availability of trained neurosurgeons, advanced visualization equipment, and procedure-specific infrastructure may support the adoption of neuroendoscopic systems in these settings. Selected procedures suitable for short-stay care may also contribute to demand where appropriate anesthesia, monitoring, and emergency support are available.

Regional Insights

The Southeast accounted for the largest share of 25.04% of the U.S. neuro endoscopy market in 2025, supported by academic medical centers, tertiary-care hospitals, and specialized neurosurgical programs performing ventricular, skull-base, and intracranial procedures. For instance, in March 2025, Duke Health introduced a multidisciplinary Pediatric Skull Base Program integrating pediatric neurosurgery, skull-base surgery, and other specialties to provide treatment options, including minimally invasive endoscopic procedures, for children with skull-base tumors.

To learn more about this report, Download Free Sample Report

The West is expected to register the fastest CAGR from 2026 to 2033, driven by specialized neurosurgical centers and the presence of neuroendoscopy devices technology developers. For instance, in October 2025, California-based Clearmind Biomedical signed an exclusive U.S. distribution agreement with Sutter Medical Technologies and launched its Neuroblade Multi-Function Neuro-Endoscope System at the Congress of Neurological Surgeons annual meeting in Los Angeles. The system integrates visualization, irrigation, suction, coagulation, and powered debridement for minimally invasive neurosurgical procedures, strengthening the region’s role in neuroendoscopy devices technology development and commercialization.

Key U.S. Neuroendoscopy Devices Company Insights

Key companies in the U.S. market are pursuing business growth strategies, including product portfolio expansion, new product development, regulatory clearances, partnerships and collaborations, and acquisitions. These initiatives are aimed at strengthening endoscopic visualization capabilities, expanding clinical applications, and increasing market presence.

Key U.S. Neuroendoscopy Devices Companies

• KARL STORZ

• B. Braun Melsungen AG (Aesculap)

• Clarus Medical LLC.

• Stryker (NICO)

• Olympus Corporation

• Richard Wolf GmbH

• Penumbra, Inc.

• Integra LifeSciences Corporation

• Medtronic

• Carl Zeiss Meditec AG

• ClearMind Biomedical Inc.

• Machida Endoscope Co., Ltd.

Recent Developments

• In July 2026, KARL STORZ announced a strategic partnerships with Moon Surgical and Sovato in the U.S. to expand its robotics ecosystem by combining 3D visualization, robotic technologies, digital capabilities, and operating room integration.

• In May 2026, Clarus Medical received FDA 510(k) clearance for the Digital ClarusScope System and Digital NeuroPEN System, expanding its digital endoscopy portfolio for diagnostic and operative endoscopic procedures involving the spine and other anatomical sites.

• In September 2025, B. Braun completed the acquisition of True Digital Surgery, a California-based developer of digital robotic-assisted 3D surgical microscopy. The acquisition strengthens Aesculap’s digital visualization capabilities and supports further development of the AEOS platform for neurosurgery, spine surgery, and ENT procedures.

• In March 2025, Integra LifeSciences received FDA 510(k) clearance for its AURORA Surgiscope System, a neurological endoscope intended for neurosurgery, endoscopic neurosurgery, and ventriculoscopy. The system integrates a single-use sheath with an integrated camera and illumination with a reusable Image Control Box for visualization during procedures such as ventriculostomy, biopsy, and removal of cysts, tumors, and other obstructions.

U.S. Neuroendoscopy Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global U.S. neuroendoscopy devices market report based on component, settings, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033), (Unit Volume, 000’ Units, 2021 - 2033), (Install Base, 000’ Units, 2021 - 2033), (ASP, Units, 2021 - 2033)

  • Rigid Neuroendoscopes

    • Disposable Rigid Neuroendoscopes

      • Disposable Rigid Ventricular Neuro endoscopes

      • Disposable Rigid Skull-base / Intracranial Neuroendoscopes Disposable Flexible Neuro endoscopes

    • Reusable Rigid Neuroendoscopes

      • Reusable Rigid Ventricular Neuro endoscopes

      • Reusable Rigid Skull-base / Transsphenoidal Neuroendoscopes

      • Reusable Rigid Cranial Neuro endoscopes Flexible Neuroendoscopes

    • Disposable Flexible Neuroendoscopes

      • Disposable Flexible Ventricular Neuroendoscopes

      • Disposable Flexible Cerebral / Intracranial Neuro endoscopes

    • Reusable Flexible Neuroendoscopes

      • Reusable Flexible Ventricular Neuroendoscopes

      • Reusable Flexible Cerebral / Intracranial Neuro endoscopes

• Settings Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

    • Inpatient

    • Outpatient

  • Neurosurgical Centers / Specialty Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033), (Unit Volume, 000’ Units, 2021 - 2033), (Install Base, 000’ Units, 2021 - 2033), (ASP, Units, 2021 - 2033)

  • Northeast

  • Southeast

  • Southwest

  • Midwest

  • West

Research Methodology

The neuroendoscopy devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each neuroendoscopy devices segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

Market-specific Research Models:

Consensus-Based Estimates & Forecasting

The U.S. neuro endoscopy devices market was estimated using supply-side and demand-side models. Public data, product evidence, existing primary research, and internal databases were used to validate the key assumptions.

The model covers 2021 to 2033. Values for 2021 to 2024 are modeled historical estimates, 2025 is the base year, and 2026 to 2033 are forecasts. All annual estimates were built from the underlying drivers rather than applying one common growth rate to every segment.

Our methodology included:

• Model 1: Commodity Flow Analysis - For publicly listed companies, annual reports, 10-K filings, investor presentations, earnings releases, and geographical revenue disclosures were reviewed. For private companies and subsidiaries, revenue information was sourced from company disclosures and premium paid databases, including S&P Global, Crunchbase, ZoomInfo, and RocketReach. Neuro endoscope revenue was derived using product portfolio, U.S. availability, FDA clearance, site-of-care suitability, market penetration, and product-level ASP.

• Model 2: Demand-based Market Sizing Framework

• Model 3: Primary Market Research Validation

• Model 4: Internal Database

• Model 5: U.S. Neuro Endoscopy Devices Market CAGR Calculations

Market Scope and Product Boundary

The market includes reusable and single-use neuro endoscopes used for endoscopic visualization in ventricular, skull-base, and selected intracranial procedures.

Introducers, access sheaths, aspiration devices, tissue-removal tools, navigation systems, cameras, processors, monitors, light sources, repair services, and reusable control units are excluded from neuroendoscope units and revenue. For transsphenoidal and skull-base surgery, general scopes are excluded unless they are specifically used as the qualifying neurosurgical visualization scope.

Model 1: Commodity Flow Analysis

Commodity flow analysis is the supply-side methodology used to derive and validate the U.S. neuro endoscopy devices market size. The approach estimates the market revenue pool from company-level financial information and product-level revenue estimates.

For publicly listed companies, financial data was sourced from annual reports, 10-K filings, investor presentations, earnings releases, and official geographical disclosures. Where companies did not report neuro endoscopy devices revenue separately, the analysis started with the reported business segment and applied a transparent revenue-allocation framework. For private companies and subsidiaries, the latest available revenue information was sourced from official company disclosures and premium databases, including S&P Global, Crunchbase, ZoomInfo, and RocketReach. The U.S. neuro endoscopy devices contribution was estimated using product breadth, U.S. commercial presence, regulatory availability, distribution coverage, installed-base potential, replacement demand, and product ASP.

To learn more about this report, Download Free Sample Report

Commodity flow analysis was employed to track the movement of U.S. neuro endoscopy devices through the value chain, from technology providers to end users. This analysis provided insights into demand generation points, intermediary roles, and ultimate consumption patterns.

Delivered Customizations

This report has been delivered with the following In-depth customizations